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Introduction  1 
Over the past decade, the field of CRISPR-Cas research has received a lot of attention from the 2 
scientific community. While initially this mostly concerned microbiologists who were fascinated 3 
by the discovery that some bacteria encode RNA-guided adaptive immune systems, this rapidly 4 
spread to other scientific disciplines following the development of groundbreaking molecular 5 
biology tools [1], and more recently to the public domain where the societal and ethical 6 
implications and legislation surrounding CRISPR applications are being heavily debated. Some 7 
of the potential CRISPR applications that are currently being explored in the lab would involve 8 
the release of CRISPR genes into confined or open environments – for example, when CRISPR 9 
would be used to protect focal bacterial species against phage infections, when it is applied to 10 
suppress the spread of antimicrobial resistance or to control vectors of disease [2-4]. One 11 
component of the societal impacts of these applications entails an assessment of the potential 12 
risks associated with these strategies (e.g. [5-7]), which requires an understanding how these 13 
CRISPR-Cas behaves in an ecological context. In this special issue we explore this question, by 14 
examining the evolutionary history of CRISPR-Cas immune systems, where they occur 15 
naturally, when they evolve and how this impacts the spread and evolution of other DNA 16 
elements. Finally we return to the question how CRISPR-Cas may be exploited in an ecological 17 
context for the benefit of human health, and the ethical challenges that are associated with this. 18 
  19 
CRISPR-Cas adaptive immune systems – a brief overview  20 
CRISPR-Cas adaptive immune systems were discovered around 15 years ago [8-11], and are 21 
estimated to exist in approximately 50% of all bacterial genomes and roughly 90% of all 22 
archaeal genomes [12]. A CRISPR immunity phenotype is genetically encoded by a so-called 23 
CRISPR locus (Clustered Regularly Interspaced Short Palindromic Repeats) – an array of 24 
repetitive and unique sequences (repeats and spacers, respectively), both of which are typically 25 
around 30 nt in length. Spacers are derived from (foreign) genetic elements, such as plasmids 26 
and viruses, and provide immunity to re-infection based on recognition of the cognate sequence 27 
(known as “protospacer”) [13-15]. Bacteria or archaea may carry a single linked array of spacers 28 
interspersed with repeats (one CRISPR locus) or multiple loci. CRISPR loci can evolve very 29 
rapidly due to insertion of new spacers and the occasional loss of spacers or deletion of the 30 
CRISPR locus itself, which can cause very closely related strains to carry unique combinations 31 
  3 
of spacer sequences, known as a CRISPR allele. The overall length of CRISPR loci will increase 1 
and decrease with the acquisition and loss of spacers, and can vary from as little as a single 2 
spacer flanked by two repeats to hundreds of spacers and repeats [16]. Since new spacers are 3 
added at the so-called leader-end of the locus, which is the sequence that contains the CRISPR 4 
promoter, CRISPR loci form an inverse chronological record of previous infections from the 5 
leader to the trailer end of the locus [17]. The extent to which different strains share the same 6 
spacer sequences in the same order (usually at the trailer end of the CRISPR locus), is commonly 7 
used to define related allele groups (RAGs) as a measure of their evolutionary relatedness.  8 
Apart from the genetic CRISPR memory, a functional CRISPR-Cas immune system also 9 
requires a set of CRISPR-associated genes (cas genes), which encode the protein machinery 10 
required for carrying out the immune response [18]. Cas operons vary in their cas gene 11 
composition and gene synteny, resulting in a classification of CRISPR-Cas systems into 2 12 
classes, 6 Types and 33 subtypes [19-22]. These diverse CRISPR-Cas variants differ in many of 13 
their mechanistic details, which have been discussed elsewhere [23, 24], yet also have 14 
commonalities in the basic steps of the immune pathway. For example, two Cas proteins – Cas1 15 
and Cas2 – are almost invariably part of CRISPR-Cas immune systems and are responsible for 16 
inserting new spacer sequences into CRISPR arrays, sometimes assisted by other Cas proteins 17 
(reviewed in [15, 25]). CRISPR transcripts are processed by either Cas proteins or housekeeping 18 
RNases [26], and the resulting processed CRISPR RNAs (crRNAs) are bound by Cas proteins to 19 
form a ribonucleoprotein complex that serves to detect and cleave complementary nucleic acid 20 
sequences [23] . 21 
 22 
Ecology and diversity of CRISPR-Cas immunity  23 
 24 
CRISPR-Cas immune systems are unevenly distributed across taxa and environments. For 25 
example, only less than half of mesophilic bacteria encode CRISPR-Cas immune systems, 26 
compared to over 90% of bacterial thermophiles and archaea (both mesophilic and thermophilic) 27 
[11, 16, 27-29]. Moreover, some uncultured bacterial lineages are virtually devoid of CRISPR-28 
Cas immune systems [30]. A recent computer learning approach suggested that abiotic factors 29 
such as oxygen levels and temperature are important predictors of whether microorganisms 30 
encode CRISPR-Cas immune systems [31]. However, the ecological drivers of CRISPR 31 
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distribution remain unclear. In this context, the key question is when CRISPR-Cas is favoured 1 
over alternative defense strategies [32]. Experimental, theoretical and correlational studies have 2 
suggested a role for viral abundance and diversity [27, 28, 33, 34], direct and indirect fitness 3 
costs of CRISPR-Cas immune systems (e.g. autoimmunity, reduced horizontal gene transfer, 4 
induced fitness costs, see below) [35-38], and epistasis with other host genes [39, 40].  5 
In natural environments, whether that be the human lung, a hot spring or a fermenter, the 6 
ecological and evolutionary impact of CRISPR depends on the population level diversity of 7 
immune alleles. The diversity of alleles in the real world may reflect the previous history of 8 
interactions and can be used to predict whether infection epidemics will occur in the future. For 9 
example, the spread of a virulent virus can eliminate immune diversity from a population by 10 
eliminating all susceptible (non-immune) cells, resulting in a selective sweep of an individual 11 
strain with a matching CRISPR allele. In the future, this immunodominance across the CRISPR 12 
allele might make a population susceptible to the subsequent epidemic spread of a new virus or 13 
other mobile element in the population. Starting with a single strain of host or virus, diversity has 14 
been shown to evolve in experimental studies [33, 41] and to protect bacteria from virus invasion 15 
[42]. Data suggest that immune diversity shapes the evolution of viral pathogens by selecting for 16 
recombinant genotypes that are more likely to escape immunity [43] and, recombinant microbial 17 
CRISPR alleles that are more likely to increase immune profiles of a single strain [44, 45].  This 18 
inevitable interaction between viruses and mobile elements with immune diversity will thereby 19 
broadly impact dynamics of multiple microbial pathogens and link their dynamics through 20 
CRISPR.   21 
 Interestingly, studies of CRISPR diversity have observed differences in different 22 
microbial species from different environments.  Leptospirillum species from acid mine drainage 23 
biofilms [43], and Sulfolobus islandicus strains from a single hot spring [46], Halophilic archaea 24 
from a saline pond [47], Heloicobacter cinaedi [48] and Pseudomonas aeruginosa from a single 25 
hospital [49] show diversity of CRISPR spacers co-exist. In contrast, Pseudomonas aeruginosa 26 
within a human lung, or Prevotella strains in a single gut sample are clonal with complete 27 
immunodominance at one time and place [49, 50]. These differences in diversity among CRISPR 28 
populations may result from difference in CRISPR dynamics or demographics (e.g. colonization 29 
bottle-necks [51]) and biological constraints (e.g. an inactive spacer acquisition machinery [52]). 30 
As CRISPR studies have mainly focused on mechanistic details, our understanding of microbial 31 
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population dynamics in real populations is surprisingly limited. Additional studies from a diverse 1 
range of CRISPR-containing organisms and their viruses, across a range of environments are 2 
needed to identify the basis for the differences in the genetic structure of CRISPR and predict 3 
how they impact epidemics and evolutionary dynamics in local populations.  4 
 5 
Co-evolution between CRISPR hosts and viruses  6 
Given the detailed molecular understanding of how CRISPR-Cas systems work, one can often 7 
predict resistance phenotypes of an individual on the basis of its genotype and that of its phage 8 
(or other foreign DNA element). Specifically, while bacteria gain resistance through the 9 
acquisition of spacers, phages and other mobile genetic elements can overcome immunity 10 
through the acquisition of “escape mutations” in (or sometimes near) the protospacer (e.g. [53, 11 
54]). The fascinating details of the biology of CRISPR immunity and phage evasion challenge 12 
the classical theoretical framework used to understand host-parasite interactions. In particular, 13 
the Lamarckian ability of CRISPR to acquire new spacers allows the bacteria to accumulate a 14 
diverse range of resistance alleles against a focal phage [28, 55, 56]. This multiplicity of 15 
resistance within individual bacteria and/or within bacterial populations can overwhelm the 16 
evolutionary potential of the phage and drive it to extinction [42, 56-58]. Alternative 17 
mechanisms of escape are also possible and, recently, a number of different anti-CRISPR (Acr) 18 
systems have been described in different phages [59]. These Acr proteins have the ability to 19 
down-regulate the immunity of CRISPR-Cas systems and allow the phage to exploit CRISPR 20 
resistant bacteria. Interestingly, this immunosuppression has been shown to require the 21 
cooperation between multiple phages, where the first phages reduce the efficacy of CRISPR-Cas 22 
and allow subsequent infections to exploit the host [60, 61].  23 
However, even if phage lack acr genes, CRISPR immunity is far from being the silver 24 
bullet against phages because it carries several different fitness costs. Some fitness costs are 25 
likely to result from the production of an effective interference against invading pathogens and 26 
mobile genetic elements [33, 62]. Some other costs are associated with self-targeting and auto-27 
immunity [35, 36]. Also, when CRISPR targets mobile genetic elements or prophages that carry 28 
some adaptive mutation for the bacteria, CRISPR immunity may also be viewed as a form of 29 
self-targeting, since immunity directly harms the bacterial host. For instance, when CRISPR 30 
targets beneficial plasmids carrying antibiotic resistance, this immunity can be counter selected 31 
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and lead to the loss of CRISPR loci [37, 63-65], potentially explaining why many bacteria lack 1 
CRISPR-Cas immune systems. Note, however, that apart from a few studies [66], the 2 
experimental study of the coevolution between CRISPR immunity and phage evasion is often 3 
limited to a few generations. The monitoring of longer coevolution experiments in the laboratory 4 
or in natural environments are very welcome to better understand the coevolutionary dynamics 5 
driven by CRISPR immunity (see several papers in this special issue). 6 
 7 
Application of CRISPR in an ecological context  8 
While CRISPR-mediated targeting of antibiotics resistance plasmids may be maladaptive for 9 
individual bacteria (see above), it was soon realized that this feature of CRISPR systems may be 10 
exploited to limit the spread of antibiotics resistance [67-69], and more generally to engineer 11 
microbial communities. As the majority of bacteria do not encode end-joining mechanisms to 12 
repair double-strand DNA breaks, CRISPR-based technologies are particularly useful for either 13 
sequence-specific killing of pathogenic bacteria or removal of accessory genes (e.g. 14 
antimicrobial resistance, virulence, etc.). Synthetic CRISPR systems can be delivered to a target 15 
bacterium using so-called phagemids, which are replication-deficient bacteriophage particles, 16 
[67, 69], or through conjugative delivery of CRISPR systems [67, 70], but research is still in its 17 
infancy and considerable challenges are associated with these approaches [3].  18 
CRISPR-mediated ecological engineering has also been explored in higher organisms, 19 
where it has raised major interest given its potential use in pest and invasive species control and 20 
reducing vector-borne diseases. Ecological engineering can be achieved by CRISPR-based 21 
genome engineering of wild animals followed by introducing these engineered animals in a local 22 
wild population. However, this method is likely to be effective only if the target population is 23 
relatively small (see Buchthal et al in this issue). A more powerful, but also riskier approach is to 24 
apply synthetic CRISPR-based gene drives [4, 71, 72]. These elements spread with super-25 
Mendelian inheritance through a population and can disrupt genetic loci or facilitate the spread 26 
of genetically linked genes. CRISPR-based gene drives have been successfully used in confined 27 
laboratory settings in a range of organisms, including yeast, fruit flies, mosquitoes and, very 28 
recently, mice [73-76], and some first insights into the evolutionary dynamics of these drives, 29 
including evolution of resistance, are emerging [77-80].  30 
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For all these ecological engineering approaches, there is a clear need to better understand 1 
the potential risks of these gene drives and whether there is any appetite in society for these types 2 
of interventions. For example, what is the durability of these interventions, what are their long-3 
term ecological consequences for (microbial) communities, and what countermeasures can be 4 
taken to limit or reverse gene drive spread? Being able to predict risks and benefits will be one 5 
important factor to get support from local communities, and for ethical and legislative approval. 6 
Recognizing the urgent need for new guidelines, scientists from a range of disciplines, including 7 
ethicists, social scientists and biologists, are working together to develop improved safety 8 
recommendations for CRISPR-based ecological engineering technologies [6, 81, 82], and ethical 9 
guidelines and the involvement of the public at an early stage in the development of these 10 
applications [81, 83, 84].   11 
 12 
Aims of the theme issue 13 
This theme issue aims to examine when and where CRISPR-Cas immune systems are important, 14 
how this impacts the coexistence and coevolution between bacteria and phages, and how this ties 15 
in with more practical and ethical considerations concerning the application of CRISPR-based 16 
technologies in an ecological context. The studies presented in this issue use a wide range of 17 
different approaches, from bioinformatics and metagenomics correlational studies to 18 
experimental and theoretical analyses, to answer an equally wide range of questions all somehow 19 
linked to CRISPR ecology and evolution: from understanding the basic principles of CRISPR 20 
evolution in bacteria to community engagement studies to examine if CRISPR-based 21 
applications can be applied in the real world to limit the spread of Lyme disease. The theme issue 22 
highlights the need to not only understand how CRISPR works in an ecological context, but also 23 
to engage with important practical issues when translating this knowledge to real-world 24 
applications to improve human health.   25 
 26 
Overview of the papers 27 
This theme issue is broadly divided into four areas that deal respectively with (i) the evolutionary 28 
history and relative importance of CRISPR-Cas immune systems, (ii) the role of CRISPR-Cas 29 
immune systems during bacteria-phage or Archaea-virus coevolution in real environments, (iii) 30 
understanding the drivers and consequences of coevolution in controlled lab environments, and 31 
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(iv) the way CRISPR may be harnessed to remove infectious diseases in real environments, and 1 
the associated considerations that need to be taken into account. 2 
 3 
A) Evolutionary history and relative importance of CRISPR-Cas immune systems 4 
One of the key questions in the field of CRISPR-Cas is how these sophisticated immune systems 5 
evolved in the first place, and how the enormous diversity of CRISPR Classes, Types and 6 
subtypes emerged in this process. Koonin & Makarova (ref) use comparative genomics to bring 7 
the evolutionary history of this system in focus. They suggest a key role for a Cas1-related 8 
transposase in the early evolution of the “Adaptation” module of the system, followed by 9 
evolution of increased complexity through a series of gene duplication and displacement events, 10 
recruitment of genes with nuclease activities and in some cases signal transduction genes to form 11 
the “Interference” module of the system. While a cloud of uncertainty inevitably surrounds such 12 
analyses, their work provides a plausible explanation for the way in which a highly complex 13 
adaptive immune system may have evolved. A next obvious question is then, why do not all 14 
bacteria and Archaea carry this adaptive immune system. This is a recurrent question, and one 15 
factor that clearly matters is how well CRISPR-Cas immune systems performs (in terms of the 16 
benefits it provides) relative to alternative immune strategies. For example, many bacteria and 17 
archaea encode restriction-modification systems or they can mutate receptors that phages use to 18 
attach to the cell surface. So why put up with CRISPR immunity, is the question that is raised by 19 
Levin and co-workers (ref). Using mathematical modeling they demonstrate that in theory the 20 
conditions where CRISPR is favoured over these alternative defenses is restricted. In other 21 
words, microbes have many options available to defend themselves against phages, and CRISPR 22 
may simply not always be the best one. However, the benefits of CRISPR are not only 23 
determined by the presence or absence of phage, but also by the genetic context of these immune 24 
systems, as Aude Bernheim and her colleagues show using bioinformatics approaches (ref), and 25 
as Anne Chevallereau and co-workers show using experimental manipulations (ref). Specifically, 26 
Bernheim et al find evidence for both positive and negative epistatic interactions between 27 
CRISPR-Cas subtypes and double stranded DNA repair pathways in bacteria. This therefore 28 
suggests that the distribution of CRISPR-Cas subtypes across bacterial species is shaped by the 29 
genetic context, but the underlying mechanism for this association is unclear. Earlier work from 30 
the same team demonstrated that one cas gene can inhibit the NHEJ pathway, which conceivably 31 
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can be maladaptive, explaining why these systems hardly ever co-occur in the same genome 1 
[39]. Chevallereau et al experimentally examined the impact of mutS, which is part of the DNA 2 
mismatch repair system, on the evolution of CRISPR resistance by Pseudomonas aeruginosa 3 
against its phage DMS3vir. They found that due to the resulting increase in mutation supply, 4 
bacteria were much more likely to evolve resistance through mutation of the phage receptor, 5 
suggesting no selective benefit of carrying CRISPR-Cas immune systems in this host genetic 6 
background. Together, these studies show how CRISPR-Cas immune systems may have evolved 7 
in the first place, and how natural selection for these systems not only depends on the presence or 8 
absence of phage, but also on the presence of alternative defense mechanisms as well as the 9 
genetic context of the CRISPR-Cas system. 10 
 11 
B) Patterns of spacer acquisition in an ecological context  12 
One of the key questions in the field of CRISPR ecology and evolution is what drives the 13 
generation and maintaince of CRISPR diversity. Using mathematical modeling, Bradde et al 14 
show that spacer acquisition rates can be constrained by a cost of autoimmunity (ref). Their 15 
model assumes that higher spacer acquisition rates not only increase the benefits of phage 16 
resistance, but also the costs of autoimmunity due to spacer sampling from the bacterial genome. 17 
This results in selection for an optimum spacer acquisition rate that maximizes bacterial survival 18 
(a balance of phage resistance and autoimmunity), which in turn depends on factors that 19 
influence the infection risk, such as bacterial and phage population sizes. In addition to this 20 
theoretical approach, several papers in this issue apply comparative population studies to 21 
describe spacer diversity in natural environments, and to identify the factors that drive this 22 
diversity. Lopatina et al. (ref) examine the CRISPR loci of populations of the bacterium Thermus 23 
in different geographical locations in Chile, Italy and Russia. They demonstrate that within a 24 
single population of the bacterium Thermus more spacers are shared among strains than among 25 
distant populations. The authors infer from the pattern that local dynamics between hosts and 26 
viruses define the local diversity although the shared spacers among populations indicate some 27 
evidence for gene flow.  Similarly, Pauly et al. (ref) show patterns of persistent local diversity 28 
within a single hot spring of Sulfolobus islandicus. Pauly also shows that these patterns vary for 29 
different viruses indicating that virus lifestyle impacts immune diversity and explore different 30 
mechanisms of CRISPR escape from different viruses through mutation or virus genome 31 
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replacement. Finally, Hoikkala et al. review the importance of CRISPR-Cas immune systems in 1 
acquaculture, and the observed dynamics of coevolution of a bacterial fish pathogen and its 2 
phage. They discuss how CRISPR diversity of bacterial strains in these environments can be 3 
exploited for tracking the epidemiology of bacterial pathogens, and for phage therapy 4 
interventions (ref). Their review highlights how a better understanding of CRISPR-diversity may 5 
be used to stabilize and shape healthy microbial populations and prevent invasions of bacterial 6 
pathogens into acquaculture environments. Collectively, these studies provide novel insights into 7 
the generation, maintenance and potential application of spacer diversity in natural 8 
environments. 9 
 10 
C) Coevolution between CRISPR-Cas immune systems and phages in the lab  11 
Experiments carried out in controlled environments in the lab allow to explore the details of the 12 
coevolutionary processes between CRISPR systems and phages. Common et al (ref) carried out a 13 
coevolution experiment between Streptococcus thermophilus and a lytic phage over 30 days. The 14 
monitoring of phenotypic and genotypic changes in both the bacteria and the phage across time 15 
confirmed the emergence of an antagonist arms race that often results in the extinction of the 16 
phage populations. These extinctions suggest that this coevolution is asymmetric because the 17 
phage cannot cope with the accumulation of escape mutations. The existence of a fitness cost 18 
associated with most escape mutations was confirmed by a separate study by Chabas et al (ref) 19 
on the same biological model. In addition, Chabas et al. found a dramatic variation in the speed 20 
at which the phage can escape different CRISPR mediated resistance alleles. The resistance 21 
induced by some spacers can be easily bypassed by the rapid emergence of escape mutations, 22 
while the resistance induced by other spacers is much more durable. The measurement of the 23 
phage mutation rate using Luria-Delbruck fluctuation tests allowed Chabas et al to suggest that 24 
this variation in resistance durability is likely to be driven by heterogeneity in the mutation rate 25 
across different protospacers. The evolution of escape mutations was also studied by Watson et 26 
al (ref) in two lytic phages infecting CRISPR resistant Pectobacterium atrosepticum. This study 27 
contrasted the evolution of the phage against single or multiple spacers. When the resistance was 28 
mediated by a single spacer, most escape mutations were due to a single point mutation in the 29 
PAM or the seed sequence. When the resistance is due to multiple spacers, most phages escaped 30 
with deletions in genes encoding structural proteins. These mutations were viable but affect the 31 
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morphology and the fitness of the virus, which further support the existence of a cost of escape 1 
and an asymmetry in the coevolutionary arms race. The details of phage adaptation was also 2 
studied by McKitterick et al (ref) in a fascinating system where the phage ICP1 uses a fully 3 
functional CRISPR-Cas system to down-regulate bacterial immunity of Vibrio cholerae 4 
mediated by a phage inducible chromosomal island-like element (PLE). High-throughput 5 
sequencing allowed the authors to monitor the acquisition of new spacers against PLE in the 6 
CRISPR of ICP1, which provide quantitative resistance against PLE that depends on the number 7 
and sequence of spacers. Furthermore, even spacers not targeting the PLE but instead targeting 8 
the small chromosome of the bacterium could still reduce bacterial immunity if the chromosomal 9 
targeting occurred close to the PLE integration site. Collectively, these different experiments in 10 
the lab shed a new light on the interference mediated by CRISPR and by the costs associated 11 
with different mutations allowing phages to escape bacterial immunity. 12 
 13 
D) Implications of CRISPR-Cas for human health and wellbeing  14 
Natural CRISPR-Cas systems can have an important impact on human health by for example 15 
altering the spread of antimicrobial resistance and virulence genes [85]. However, even though 16 
experimental studies show that CRISPR-Cas forms an important barrier for horizontal gene 17 
transfer, correlational studies have shown mixed results [63, 86]. Here, Shereen et al (ref) 18 
examine if the presence of anti-CRISPR genes may impact the correlation between CRISPR-Cas 19 
immune systems and antibiotic resistance genes (ARGs) genes. They find a very high degree of 20 
variation between bacterial species in the abundance of CRISPR-Cas systems and no correlation 21 
with ARG for most species. However, for Pseudomonas aeruginosa they found a positive 22 
correlation between anti-CRISPR and ARG genes, indicating that anti-CRISPRs may facilitate 23 
the spread of clinically relevant genes such as those encoding antibiotic resistance or virulence 24 
factors in the face of CRISPR-Cas immune systems. These genes may be removed using 25 
CRISPR-based ecological engineering technologies. Although this is still a very young field the 26 
developments have moved fast and scientists now have a variety of CRISPR-based tools at hand 27 
to alter microbiome composition and function, and use them as next-generation antimicrobials. 28 
Ramachandran & Bikard (ref) provide a thorough overview of the these various CRISPR-based 29 
applications to alter the microbiome, including its application in editing bacteria and phage 30 
genomes, controlling their gene expression using CRISPRi, killing pathogenic bacteria using 31 
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CRISPR-based antimicrobials and removing antibiotic resistance genes or other virulence 1 
determinants.  2 
 While these CRISPR-based ecological engineering approaches have great potential to 3 
solve ecological problems, there are many technological, regulatory, societal and ethical 4 
challenges. In this issue, De Graeff et al (ref) provide a thorough overview of the arguments 5 
reported in the scientific literature for and against genome editing in animals, including gene 6 
drives, which relate to human health, efficiency, risks and uncertainty, animal welfare, animal 7 
dignity, environment and public acceptability. The authors also pointed out that the ethical 8 
debate on genome editing in animals is predominantly shaped by biomedical and veterinary 9 
scientists, and less so by ethicists and social scientists. They argue that involvement of ethicists 10 
and social scientists from the very early research stages of technology development may help 11 
facilitate responsible governance of animal genome editing applications [87]. Furthermore, there 12 
is a need for engagement with the public to address amongst others concerns around equity of 13 
access (who will benefit from the new technology?) and the commercialization of the technology 14 
(will businesses prioritize profit-making over providing a safe public good?). Buchthal et al (ref) 15 
provide an excellent example of involving the public in decision-making on CRISPR-based 16 
ecological engineering. ‘Mice against Ticks’ is an exciting new community-guided ecological 17 
engineering project aimed at reducing the incidence of tick-borne diseases vectored by mice on 18 
the islands of Nantucket and Martha’s Vineyard off the US east coast. Their idea is to introduce 19 
CRISPR-edited mice that are heritably resistant to ticks and/or tick-borne disease in the islands’ 20 
local mouse population, which is hypothesized to disrupt the disease transmission cycle. From 21 
the stages of conception of the project the local communities of both islands have been actively 22 
involved in all decision-making. Although at a relatively early stage still, successes and 23 
challenges from this exciting pilot project will provide future ecological engineering projects 24 
with highly valuable insights on how to set up community-driven projects. 25 
 26 
Conclusion and outlook  27 
While our mechanistic understanding of CRISPR-Cas immune systems has raced ahead, our 28 
understanding of the evolutionary ecology of these fascinating immune systems is still relatively 29 
limited. As outlined above, this issue fills some important gaps in our knowledge of the 30 
distribution and impact of CRISPR immune systems, but there are also many outstanding 31 
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questions that need to be answered. For example, why are there so many different CRISPR-Cas 1 
variants, what are their costs and benefits, and how does this depend on the environment? Why 2 
do so many bacteria not encode CRISPR-Cas immune systems, and what drives their loss? Why 3 
is it that in the lab bacteria that encode CRISPR-Cas systems often evolve receptor-based 4 
resistance against their phages? Is this because of a lack of ecological realism, widespread anti-5 
CRISPR strategies of phages, or are as yet unknown phage life history traits important for the 6 
evolution of CRISPR resistance? As argued in this introduction, a better understanding of the 7 
principles that govern evolution of CRISPR-Cas immune systems and their coevolution with 8 
mobile genetic elements can help to inform applications of CRISPR-based technologies in real 9 
environments. Apart from this quest for a better understanding of CRISPR ecology and 10 
evolution, contributions in this issue also highlight the need for community engagement by 11 
CRISPR biologists and participation in debates surrounding the ethics and legislative aspects of 12 
these technologies, and provide some excellent examples of how this can be done. 13 
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